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Abstract
Glioblastoma multiforme (GBM) is one of the most deadly types of cancer. To date, the best clinical approach for
treatment is based on administration of temozolomide (TMZ) in combination with radiotherapy. Much evidence
suggests that the intracellular level of the alkylating enzyme O6-methylguanine–DNA methyltransferase (MGMT)
impacts response to TMZ in GBM patients. MGMT expression is regulated by the methylation of its promoter.
However, evidence indicates that this is not the only regulatory mechanism present. Here, we describe a hitherto
unknown microRNA-mediated mechanism of MGMT expression regulation. We show that miR-221 and miR-222 are
upregulated in GMB patients and that these paralogues target MGMT mRNA, inducing greater TMZ-mediated cell
death. However, miR-221/miR-222 also increase DNA damage and, thus, chromosomal rearrangements. Indeed,
miR-221 overexpression in glioma cells led to an increase in markers of DNA damage, an effect rescued by re-
expression of MGMT. Thus, chronic miR-221/222-mediated MGMT downregulation may render cells unable to repair
genetic damage. This, associated also to miR-221/222 oncogenic potential, may poor GBM prognosis.
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Introduction
Glioblastoma multiforme (GBM) is the most common and
deadly primary tumor of the central nervous system. Despite
several therapeutic advances, the prognosis for GBM remains
poor, with a median survival lower than 15 months [1,2].
Currently, first-line therapy for GBM comprises surgery with the
maximum feasible resection, followed by a combination of
radiotherapy and treatment with the alkylating agent
temozolomide (TMZ), also referred to by its brand name
Temodal [3,4,5]. TMZ is a methylating agent that modifies DNA
in several positions, one of them being O6-methylguanine MeG
(O6MeG) [6]. If the methyl group is not removed before cell
division, this modified guanine preferentially pairs with thymine
during DNA replication, triggering the DNA mismatch repair
(MMR) pathway, DNA double-strand breaks, and, therefore,
the apoptotic pathway [7,8]. O6-methylguanine–
methyltrasferase (MGMT) is a suicide cellular DNA repair
enzyme ubiquitously expressed in normal human tissues.
MGMT does not act as a part of a repair complex but works
alone [9]. To neutralize the cytotoxic effects of alkylating
agents, such as TMZ, it rapidly reverses alkylation at the O6
position of guanine, transferring the alkyl group to an internal
cysteine residue in its active site. In this form, the enzyme is
inactive and, thus, requires de novo protein synthesis. In
tumors, high levels of MGMT activity are associated with
resistance to alkylating agents [10]. In contrast, epigenetic
silencing of MGMT gene expression by promoter methylation
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results in sensitization to therapy [11,12]. However, some
studies have reported that MGMT promoter methylation does
not always correlate with MGMT expression and with response
to therapy [13,14]. Therefore, the existence of other
mechanisms of MGMT regulation should be postulated.
MicroRNAs (miRs) are small regulatory molecules that have
a role in cancer progression and in tumor therapy response
[15,16]. By negatively regulating the expression of their targets,
miRs can act as tumor suppressors or oncogenes [17]. miRs
may also regulate DNA damage response and DNA repair,
interfering with the response to chemotherapy or radiotherapy
[18]. Several studies have indicated that the modulation of miR
expression levels is a possible therapeutic strategy for cancer.
The paralogues miR-221 and miR-222 have frequently been
found to be dysregulated in glioblastoma and astrocytomas
[19,20,21,22]. Their upregulation increases glioma cell
proliferation, motility, and in vivo growth in mouse models.
miR-221/222 have also been shown to be implicated in cellular
sensitivity to tumor necrosis factor-related apoptosis-inducing
ligand (TRAIL)-treatment [23,24,25]. In this manuscript, we
provide evidence that miR-221 and miR-222 regulate MGMT
expression levels in glioblastoma, increasing the response to
TMZ, but due to their oncogenic potential, affect overall patient
survival negatively.
Materials and Methods
Cell culture and transfection
U87MG, T98G, LN428, LN308, A172, and HEK-293 cells
were grown in DMEM. LN229 were grown in Advanced DMEM
(Gibco, Life technologies, Milan, Italy). T98G, U87MG, and
LN229 were from ATCC (LG Standards, Milan Italy); LN428,
LN308, and A172 were kindly donated by Frank Furnari (La
Jolla University). Media were supplemented with 10% heat-
inactivated fetal bovine serum (FBS) -5% FBS for LN229 -2
mM L-glutamine, and 100 U/ml penicillin/streptomycin. All
media and supplements were from Sigma Aldrich (Milan, Italy).
For overexpression of miRs, cells at 50% confluency were
transfected using Oligofectamine (Invitrogen, Milan, Italy) and
100nM pre-miR-221 or pre-miR-222, a scrambled miR or anti-
miR-221/222 (Applied Biosystems, Milan, Italy). For
overexpression of MGMT, cells were transfected using
Lipofectamine and Plus Reagent with 4 µg of MGMT cDNA
(Origene, Rockville MD USA). Temozolomide was purchased
from Sigma Aldrich (Milan, Italy).
Human Glioma samples
A total of 34 formalin-fixed, paraffin-embedded (FFPE) tissue
samples were collected from the archives of the Department of
Pathology, University Hospital of Kuopio, Finland. Permission
to use the material was obtained from the National Supervisory
Authority for Welfare and Health of Finland, and the study was
accepted by the ethical committee of the Northern Savo
Hospital District, Kuopio, Finland.
Primary cell cultures
Glioblastoma specimens were obtained as previously
described [19]. Samples were mechanically disaggregated, and
the lysates grown in DMEM-F12 medium supplemented with
10% FBS, 1% penicillin streptomycin, and 20 ng/ml epidermal
growth factor (EGF; Sigma-Aldrich, Milan, Italy). To determine
the glial origin of the isolated cells, we stained the cultures for
glial fibrillary acidic protein (GFAP), a protein found in glial
cells.
Protein isolation and Western blotting
Cells were washed twice in ice-cold PBS and lysed in JS
buffer (50 mM HEPES pH 7.5 containing 150 mM NaCl, 1%
Glycerol, 1% Triton X100, 1.5mM MgCl2, 5mM EGTA, 1 mM Na
3VO4, and 1X protease inhibitor cocktail). Protein concentration
was determined by the Bradford assay (BioRad, Milan, Italy)
using bovine serum albumin (BSA) as the standard, and equal
amounts of proteins were analyzed by SDS-PAGE (12.5%
acrylamide). Gels were electroblotted onto nitrocellulose
membranes (GE Healthcare, Milan, Italy). For immunoblot
experiments, membranes were blocked for 1 hr with 5% non-fat
dry milk in Tris-buffered saline (TBS) containing 0.1%
Tween-20, and incubated at 4°C overnight with primary
antibody. Detection was performed by peroxidase-conjugated
secondary antibodies using the enhanced chemiluminescence
system (GE Healthcare, Milan, Italy). Primary antibodies used
were: anti-β-actin from Sigma-Aldrich (Milan Italy); anti-
caspase-3 and anti-PARP from Santa Cruz Biotechnologies
(Santa Cruz, CA, USA), anti-γH2AX from Millipore (Milan,
Italy), anti-p53, pser15 p53, and phosphorylated-ATM from Cell
Signaling Technology (Milan, Italy).
RNA extraction and Real-Time PCR
Cell culture: Total RNA (microRNA and mRNA) were
extracted using Trizol (Invitrogen, Milan, Italy) according to the
manufacturer’s protocol.
Tissue specimens
Total RNA (miRNA and mRNA) from FFPE tissue specimens
was extracted using RecoverAll Total Nucleic Acid isolation Kit
(Ambion, Life Technologies, Milan, Italy) according to the
manufacturer’s protocol. Reverse transcription of total miRNA
was performed starting from equal amounts of total RNA/
sample (1µg) using miScript reverse Transcription Kit (Qiagen,
Milan, Italy), and with SuperScript® III Reverse Transcriptase
(Invitrogen, Milan, Italy) for mRNA. Quantitative analysis of
MGMT, β-actin (as an internal reference), miR-221, miR-222,
and RNU5A (as an internal reference) were performed by
RealTime PCR using specific primers (Qiagen, Milan, Italy),
miScript SYBR Green PCR Kit (Qiagen, Milan, Italy), and iQTM
SYBR Green Supermix (Bio-Rad, Milan, Italy), respectively.
The reaction for detection of mRNAs was performed as follows:
95°C for 15’, 40 cycles of 94°C for 15″, 60°C for 30″, and 72°C
for 30″. The reaction for detection of miRNAs was performed as
follows: 95°C for 15’, 40 cycles of 94°C for 15″, 55°C for 30″,
and 70°C for 30″. All reactions were run in triplicate. The
threshold cycle (CT) is defined as the fractional cycle number
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at which the fluorescence passes the fixed threshold. For
relative quantization, the 2(-ΔCT) method was used as previously
described [26]. Experiments were carried out in triplicate for
each data point, and data analysis was performed by using a
Bio-Rad software (Bio-Rad, Milan, Italy).
Luciferase assay
The 3’ UTR of the human MGMT gene was PCR amplified
using the following primers: MGMT-Fw:
5’TCTAGAGTATGTGCAGTAGGATGGATG3’; MGMT-Rv: 5’
TCCAGAGCTACAGGTTTCCCTTCC3’, and cloned
downstream of the Renilla luciferase stop codon in pGL3
control vector (Promega, Milan, Italy). A deletion was
introduced into the miRNA-binding sites with the QuikChange
Mutagenesis Kit (Stratagene, La Jolla CA USA) using the
following primers: MGMT-mut Fw: 5’
CTATATCCAAAAGGGAAACCTGTAGCTCTTGC 3’. MGMT-
mut Rw: 5’- GCAGAGCTACACGTTTCCCTTTTGGATATAG 3’.
HEK-293 cells were co-transfected with 1.2µg of plasmid and
400 µg of a Renilla luciferase expression construct, pRL-TK
(Promega, Milan, Italy), with Lipofectamine 2000 (Invitrogen,
Milan, Italy). Cells were harvested 24 hrs post-transfection and
assayed with Dual Luciferase Assay (Promega, Milan, Italy)
according to the manufacturer’s instructions. Three
independent experiments were performed in triplicate.
Cell death quantification
Cell viability was evaluated with the CellTiter 96 AQueous
One Solution Cell Proliferation Assay (Promega, Milan, Italy)
according to the manufacturer’s protocol. Metabolically active
cells were detected by adding 20 µL of MTS to each well. After
2 hrs of incubation, the plates were analyzed in a Multilabel
Counter (BioTek, Milan, Italy). For caspase-3 inhibition
experiments, ZVAD-Fmk was purchase from Calbiochem.
Comet assay
Alkaline comet assay was performed accordingly to
manufacturer’s instructions (Trevigen, Gaithersburg, Maryland,
USA). Briefly, 12x104 glioblastoma cell lines were transfected
with miRs or MGMT cDNA and then treated with TMZ in 6-well
plates. Cells were collected and then combined with
LMAgarose. The mixture was applied to Comet slides and kept
at 4°C in the dark for 10’. The slides were immersed in pre-
chilled lysis buffer for 30 min. The slides were washed and then
electrophoresis was carried out. The slides were fixed in 70%
ethanol for 5 min and let dry overnight. SYBR green was added
and comets were photographed at 100 x microscopes (Carl
Zeiss Inc., NY, USA).
γH2AX flow cytometric analysis
Treated cells were fixed with 2% paraformaldehyde for 1 hr.
Fixed cells were permeabilized with 0.1% Triton-X100/PBS for
5 min on ice. Blocking was done in PBS+2% BSA. Anti-
phosphorylated H2Ax antibody(Ser139, γH2Ax, Millipore,
Milan, Italy) was diluted in PBS and then FITC-conjugated goat
anti-mouse antibody (Santa cruz Biotechnology, CA, USA) was
used. Cells were analyzed with a Becton Dickinson FACScan
flow cytometer.
Caspase Assay
The assay was performed using the Colorimetric CaspACETM
Assay System, (Promega, Milan, Italy) as reported in the
instruction manual. Briefly, T98G cells were transfected with
miR-221 and/or MGMT cDNA, plated in 96-well plates, and
then treated with 300 µMol of temozolomide or with 10 µMol of
ZVAD-Fmk. After treatments, 100 µl caspase-3/-7 reagent was
added to each well for 1 hr in the dark. The plates were
analyzed in a Multilabel Counter (BioTek, Milan, Italy).
MGMT Methylation Analysis
DNA methylation status in the CpG island of MGMT was
established by PCR analysis of bisulfite modified genomic
DNA, which induces chemical conversion of unmethylated, but
not methylated, cytosine to uracil. DNA was extracted from cell
lines using the DNeasy blood and tissue kit (Qiagen, Milan,
Italy). DNA (1 µg) was modified with sodium bisulfite using the
EZ DNA methylation-gold kit (Zymo Research, CA, USA)
according to the manufacturer’s instructions. Methylation-
specific polymerase chain reaction (MSP) was performed with
primers specific for either methylated or the modified




primer), and for the methylated reaction they were
5'TTTCGACGTTCGTAGGTTTTCGC3' (forward primer) and
5'GCACTCTTCCGAAAACGAAACG3' (reverse primer.) The
annealing temperature was 59°C. The cell line SW48 and in
vitro methylated DNA (CpGenome Universal Methylated DNA,
Millipore) were used as a positive control for the methylation of
MGMT and DNA from normal lymphocytes used as a negative
control. Controls without DNA were used for each set of
methylation-specific PCR assays. The methylation-specific
PCR product was loaded directly onto 2% agarose gels,
stained with syber safe, and examined under ultraviolet
illumination.
Colony Assay
Cells were transfected with scrambled miR or miR-221 for 24
hrs, harvested, and 2.4 x104 cells plated in 6-well plates. After
24 hrs, cells were treated with 300 µMol TMZ for 24 hrs, as
indicated. Cells were transferred to 100-mm dishes and grown
for 6 days. Finally, the cells were colored with 0.1% crystal
violet dissolved in 25% methanol for 20 min at 4°C. Dishes
were washed with water, left to dry on the bench, and then
photographs taken.
Statistical analysis
Student’s t test and nonparametric Mann-Whitney tests were
used to determine differences between values for normally
and, respectively, not normally distributed variables. A
probability level <0.05 was considered significant throughout
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the analysis. Data were analyzed with GraphPad Prism (San
Diego, CA, USA) for Windows.
Results
Sensitivity of human glioma cell lines to temozolomide
We analyzed the sensitivity to TMZ of human glioma cell
lines by exposing the cells to 300 µMol TMZ for 48 hours and
then assessing cell viability with the MTT assay (Figure 1A).
We observed different TMZ sensitivities, which correlated with
MGMT levels analyzed by Western blot (Figure 1B). We also
observed an inverse correlation between the level of MGMT
(Figure 1B) and miR-221 expression in glioma cell lines (Figure
1C). An RNA hybrid alignment bioinformatics search identified
a possible binding site for miR-221/222 at position 970 of the 3’
UTR of MGMT.
To examine whether miR-221/222 interfered with MGMT
expression by directly targeting the predicted 3’ UTR region,
we cloned this region downstream of a luciferase reporter gene
in the pGL3 vector. HEK-293 cells were co-transfected with the
reporter plasmid plus the negative control miR (scrambled
miR), miR-221, or miR-222. Only transfection of either miR-221
or miR-222 with the wild-type MGMT-3’UTR reporter plasmid
led to a significant decrease of luciferase activity. On the
Figure 1.  TMZ sensitivity and MGMT and miR-221/222
expression in glioma cells.  (A) Glioma cells were treated
with TMZ (300µMol) for 24 hr. Cell viability was evaluated with
an MTT assay. (B) Western blot analysis of MGMT expression
in glioblastoma cells. (C) Real time PCR of miR-221 expression
in glioblastoma cells. (D) RNA Hybrid prediction analyzes of
miR-222, miR-221, and MGMT 3’ UTR. In bold are shown the
mutated oligonucleotides. Luciferase activity of HEK-293 cells
transiently co-transfected with the luciferase reporter containing
wild-type MGMT-3’UTR or mutant MGMT-3’UTR in the
presence of pre-miR-222, miR-221, or scrambled
oligonucleotide. Representative of at least three independent
experiments. *** p<0.001 versus control, ** p<0,0037 versus
control.
doi: 10.1371/journal.pone.0074466.g001
contrary, co-expression of the scrambled miR had no effect
(Figure 1D). In addition, miR-221/222’s effect on the promoter
of MGMT was reduced with the mutant MGMT-3’UTR reporter,
in which the seed sequence was mutated. Together, these
results demonstrate that miR-221/222 directly target
MGMT-3’UTR, thereby reducing MGMT expression.
miR-221/222 target MGMT protein and mRNA
In order to establish a causal link between miR-221/222 and
MGMT expression, we transfected T98G cells with either pre-
miR-221 or pre-miR-222 for 72 hrs and then analyzed MGMT
levels by Western blot and real time-PCR. Upon miR
transfection, MGMT protein and mRNA were downregulated
(Figure 2A). In contrast, MGMT expression was increased
upon transfection with anti-miR-221 or -222 in U87MG cells
(Figure 2B). Similarly, miR-221/222, induced downregulation of
MGMT in LN428 cells, another TMZ-resistant glioma cell line
(Figure 2C), and in A375 cells, a TMZ-resistant melanoma cell
line (Figure 2D). Since MGMT expression is mainly dependent
on the methylation status of its promoter [27], we determined if
miR-221/222 acted by modulating MGMT promoter
methylation. To this end, we performed a bisulfite modification
assay by PCR using specific primers for both methylated and
unmethylated MGMT promoter. As shown in Figure 2E,
miR-221/222 expression in T98G cells, or anti-miR expression
in U87MG cells, did not modify the methylation profile of the
MGMT promoter.
miRs-221/222 modulate TMZ sensitivity in glioma cells
To verify if miR-221/222 play a role in the modulation of TMZ
sensitivity because of their effects on MGMT expression, we
characterized the viability of T98G, LN428, and A375 cells
transfected with miR-221/222 and then treated with TMZ for 24
hrs. As shown in Figure 3A, miR-221/222 transfection
increased the response to TMZ. These results were also
confirmed by proliferation and colony assays (Figure 3B and
3C). To establish a causal link between miR-221 expression
and MGMT downregulation, we performed a rescue experiment
with simultaneous overexpression of miR-221 and MGMT
cDNA in two different cell lines (T98G and LN428). As shown in
Figure 3D, the effect of miR-221 on TMZ response was
abolished by MGMT overexpression. We then verified in nine
different glioblastoma primary cell lines and in six glioma cell
lines any correlation between miR-221 expression and TMZ
sensitivity. As shown, TMZ sensitivity positively correlated with
the expression level of miR-221 (Figure 3E).
miR-221 promotes apoptotic cell death
In order to evaluate the mechanism of TMZ-induced cell
death, we assessed the presence of apoptotic cells by PI
staining and flow cytometry upon miR-221 transfection and
TMZ treatment. We found that TMZ increased apoptotic cell
death in miR-221-overexpressing cells compared with control
cells. Interestingly, this effect was rescued by the co-
expression of MGMT cDNA with miR-221 (Figure 4A).
Caspase-3/7 activation assay further confirmed the
involvement of the apoptotic machinery. As shown in Figure
4B, miR-221 expression increased caspase-3 activity upon
MicroRNA, MGMT, Glioma and Temozolomide Resistance
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TMZ treatment, while the co-expression of MGMT cDNA with
miR-221 abolished this effect. Simultaneous treatment with the
caspase inhibitor ZVAD-fmk and TMZ was able to decrease
caspase activity, confirming that TMZ induced cell death by a
caspase-mediated mechanism. Caspase-3 activation,
observed by Western blot in miR-221-transfected cells after 24
hrs of TMZ treatment, was rescued by MGMT cDNA (Figure
4C). Coherently, we observed an increase in cell viability after
miR-221 transfection and simultaneous treatment with TMZ
and ZVAD-fmk (Figure 4D).
miR-221 promotes DNA damage after TMZ treatment
MGMT activity repairs DNA by removing DNA adducts
caused by TMZ treatment. The absence of MGMT increases
cell death upon exposure to TMZ, but, as a long-term effect,
may increase DNA damage, and thus the accumulation of
mutations. We investigated whether miR-221 may increase
DNA damage upon TMZ treatment by down-modulating MGMT
expression. This was assessed by a comet assay, which
quantifies double-stranded DNA (dsDNA) breaks, in T98G cells
transfected with miR-221 or a scrambled sequence and then
treated with TMZ at different times. We found that miR-221
produced a significant enhancement of dsDNA breaks (Figure
5A). To strengthen our hypothesis, we looked for the
phosphorylation status of histone H2AX (γH2AX) at Ser139,
which reflects dsDNA break formation. As shown in Figure 5B,
Figure 2.  miR-221/222 target MGMT.  (A) Western blot
analysis and real time PCR of MGMT protein and RNA after
miR-221/222 transfection of T98G cells. (B) Western blot
analysis and real time PCR of MGMT protein and RNA after
anti-miR-221 and -222 transfection of U87MG cells. (C)
Western blot of MGMT expression upon miR-221 transfection
of LN428 cells. (D) Western blot analysis of MGMT expression
in T98G cells, as a control, and the melanoma cell line A375
upon miR-221 transfection. (E) Analysis of methylation status
of MGMT promoter in T98G and U87MG upon miR- or anti-
miR-221/222 transfection. U is for the un-methylated form, M
for methylated form, NL is for normal lymphocytes, used as
control.
doi: 10.1371/journal.pone.0074466.g002
miR-221 significantly increased γH2AX, as assessed by
immunocytofluorescence (upper panel) or by Western blot
(lower panel), suggesting that miR overexpression may induce
DNA damage. This effect was even stronger in the presence of
TMZ, but was rescued by MGMT cDNA (Figure 5B, middle
panel). Furthermore, we also observed an increase of other
DNA damage markers, such as P-ATM, P-p53ser15 and PARP
cleavage, upon miR-221 transfection; this was even stronger
upon treatment with both miR-221 and TMZ (Figure 5C). These
effects were rescued by the simultaneous expression of MGMT
with miR-221. Taken together, these data suggest that the
targeting of MGMT by miR-221 increases DNA damage. This
effect was amplified by TMZ treatment.
MGMT and miR-221 expression in glioblastoma
patients
We then evaluated the expression of MGMT and miR-221 in
human glioblastoma samples. Patients were clustered into two
separate groups: a long survival (survival >15 months) group
and a short survival (survival <15 months) group, according to
common classification [2].
We first analyzed the methylation profile of the MGMT
promoter, and then MGMT mRNA and miR-221 levels. We
performed methylation-specific PCR (MSP) on 33 human
Figure 3.  miR-221 modulates TMZ sensitivity.  (A) Cell
viability of T98G, LN428, and A375 cells transfected with
miR-221 and miR-222 upon TMZ treatment (300 µMol) for 24
hrs. **p value<0.0082 versus scr column, ***p value<0.005
versus scr column. (B) Growth curve of T98G and LN428 cells
transfected or not with miR-221 after 24 hrs of treatment with
TMZ. (C) Colony assay of T98G and LN428 cells transfected
with miR-221 and then treated for 24 hrs with TMZ (300 µMol).
Cells were left to grow for 6 days after treatment removal. (D)
MGMT expression rescues cell viability after TMZ treatment in
T98G and LN428 cells overexpressing miR-221 **p
value<0.0082 versus untransfected MGMT column. (E)
Correlation between miR-221 expression and TMZ sensitivity in
nine primary glioblastoma cell lines and in six glioblastoma cell
lines.
doi: 10.1371/journal.pone.0074466.g003
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glioblastoma paraffin-embedded tissues, and found 27 to be
unmethylated and 4 to be methylated (samples 2, 21, 22, and
28) (Figure S1). For two samples (#31 and #32), it was not
possible to define the MGMT promoter methylation profile. We
then analyzed the effect of miR-221 on MGMT regulation
among 15 unmethylated samples from which we obtained
sufficient RNA for real time PCR analysis. We identified 4 long-
(#1, #4, #10, and #14) and 11 short- (#6, #7, #8, #12, #13, #17,
#18, #23, #25, #32, and #33) survival patients. We found that
the short-survival group exhibited a higher miR-221 level and a
lower MGMT level compared with the long-survival group
(Figure 6 A,B). These data supports our in vitro evidence of an
inverse correlation between miR-221 and MGMT expression.
Furthermore, this observation identifies miR-221 as a negative
prognostic factor for survival.
Discussion
Much evidence suggests that the intracellular level of the
alkylating enzyme MGMT affects TMZ response in GBM
patients [10,11]. Low levels of MGMT are associated with a
better TMZ response, because in the absence of MGMT the
cells are not able to repair the TMZ-induced base mismatch.
Figure 4.  miR-221 promotes DNA damages upon TMZ
treatment.  (A) Apoptotic cell death assessed by FACS in
T98G cells transfected with miR-221 or scrambled sequence
and MGMT and treated with TMZ for 24 hrs. *** p value< 0.005
versus untrasfected MGMT column. (B) Active caspase-3
quantification in T98G cells as indicated and treated with TMZ
for 24 hrs in the presence or absence of 3 hrs pre-treatment
with ZVAD-fmk. (C) Upper panel Time course analysis of
caspase-3 activation upon TMZ treatment in T98G cells
transfected with miR-221 or with scrambled sequence. Lower
panel Western blot analysis of caspase-3 activation after
miR-221 and MGMT transfection. (D) Cell viability of T98G
cells transfected with miR-221 or with scrambled sequence
treated with TMZ for 24 hrs in the presence or absence of 3 hrs
pre-treatment with ZVAD-fmk. ** p value< 0.0034 versus only
treated TMZ column, Student’s t test.
doi: 10.1371/journal.pone.0074466.g004
Hence, double-strand DNA breaks, DNA mismatch repair, and
the apoptotic pathway are activated. MGMT expression is
regulated by the methylation of its promoter. MGMT promoter
methylation lowers MGMT levels and accounts for a greater
TMZ response when associated with radiotherapy. However, a
fraction of patients with unmethylated MGMT show some TMZ
response, suggesting that promoter methylation is not the only
regulatory mechanism of MGMT expression [13,14].
In the present study, we addressed this specific issue by
investigating the involvement of miRs in MGMT regulation.
First, we characterized TMZ sensitivity in a subset of
Figure 5.  miR-221 promotes DNA damage.  (A) Alkaline
comet assay of T98G cells transfected with miR-221 and
treated with TMZ for the indicated times. (B) Analysis of γH2AX
in T98G cells transfected with scrambled control miR or
miR-221, treated with TMZ in the presence or in the absence of
MGMT cDNA, by immunocytofluorescence (upper and medium
panel) or by Western blot (lower panel). (C) Western blot
analysis of the indicated proteins upon transfection of T98G
cells with miR-221 and MGMT cDNA and TMZ treatment for 24
hrs.
doi: 10.1371/journal.pone.0074466.g005
Figure 6.  Association of miR-221 and MGMT
expression.  Mann–Whitney U test analysis was performed to
evaluate the association between miR-221 and MGMT
expression in long- and short -survival groups of patients. The
expression of miR-221 (2^-Dct) (A-B) and MGMT (2^-Dct) are
inversely correlated with patient survival (p < 0.0490 and
p = 0.043, respectively).
doi: 10.1371/journal.pone.0074466.g006
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glioblastoma cell lines and primary cells obtained from GBM
patients. We found that the analyzed glioblastoma cell lines
(T98G, LN428, U87MG, and A172) expressed different levels
of miR-221/222 and displayed a consistent difference in MGMT
expression. This inverse correlation was also observed in
glioblastoma biopsies.
Bioinformatics identified a possible miR-221/222 binding site
on MGMT. This was confirmed by a luciferase assay and
overexpression experiments. The effect of miR-221/222 on
MGMT levels was direct and not related to MGMT promoter
methylation, since miR transfection did not alter the MGMT
methylation profile. Instead, we found evidence that
miR-221/222 regulated MGMT levels, leading to increased
TMZ-induced apoptosis, reduced anchorage-independent
growth, and reduced cell viability. Overexpression of MGMT
cDNA with miR-221/222 rescued the effects on TMZ sensitivity.
This result was not restricted to glioma cells, but was obtained
also in other cancer cells sensitive to TMZ, such as human
malignant melanoma.
It has been demonstrated that MGMT may be a target also of
other miRs, such as miR-181, in GBM [28]. Zhang et al.
demonstrated that miR-181d targets MGMT 3’ UTR, and
reported an inverse correlation between miR-181d and MGMT
levels in human GBM samples, in particular in those samples in
which the MGMT promoter was unmethylated [28]. However,
the modest correlation between miR-181d and MGMT
suggested that other miRs may regulate MGMT expression.
Therefore, miR-221/222 may be part of this cohort.
MGMT expression may be regulated also thought the p53
pathway. Blough et al. provided evidence that p53 regulates
MGMT expression in murine astrocytes, and presented data
suggesting that p53 contributes to the regulation of MGMT
gene expression in the human astrocytic glioma cell line SF767
[29].
In this manuscript, we demonstrate that miR-221
overexpression increases DNA damage in glioma cells. In fact,
miR-221-overexpressing glioma cells exhibited an increase in
DNA damage markers, such as P-ATM, P-p53, cleaved PARP,
and γH2AX. These markers were activated even in the
absence of TMZ, and became increased upon TMZ treatment.
MGMT participates in the repair of DNA. Thus, miR-221/222
induces chronic MGMT downregulation, rendering the cells
unable to repair DNA damage. It is well established that
miR221/222 are oncogenic microRNAs that are upregulated in
a number of human tumors [30,31,32]. In GMB tissue and cell
lines, upregulated miR-222 and miR-221 expression correlated
with the stage of the disease, cell motility, and TRAIL response
[19,23,31,33]. We found that miR-221 is a negative prognostic
factor, since it is up regulated in short-survival patients and is
downregulated in long-survival ones. However, we did not
observe the expected correlation between miR-221 expression
and response to temozolomide/survival. Arguably, overall
survival and therapy response have to be linked to other
factors. It therefore seems that the pro-oncogenic effect of
miR-221 is more powerful than its potentiation of the response
to temozolomide.
The role of MGMT in DNA damage repair has been
investigated also in animal models. Reduced expression of this
repair enzyme has been thought to result in a spontaneous
‘mutator’ phenotype and to promote neoplastic lesions in the
presence of either endogenous or exogenous sources of
alkylation stress. Sakumi, et al. showed that Mgmt−/− mice
develop thymic lymphomas and lung adenomas to a greater
extent when exposed to methylnitrosourea (MNU), suggesting
that the DNA repair methyltransferase protected these mice
from MNU-induced tumorigenesis [34]. Sandercock et al.
reported that MGMT-deficient cells exhibited an increased
mutational burden, but only following exposure to specific
environmental mutagens [35]. Takagi et al. demonstrated that
mice with mutations in Mgmt as well as in the DNA mismatch
repair gene Mlh1 developed numerous tumors after being
administered MNU. When exposed to a sub-lethal dose of
MNU (1mM), the mutation frequency in Mgmt−/−/Mlh1−/− cells
was up to 12 times that of untreated cells; this effect was not
present in control mice [36]. Walter et al. generated transgenic
mice overexpressing MGMT in brain and liver, or in lung [37].
They found that expression of the transgene correlated with a
reduced prevalence of MNU-induced tumors in liver and in lung
and also with reduced spontaneous hepatocellular carcinoma.
Reese et al. found that overexpression of MGMT decreased
the incidence and increased the latency of thymic lymphoma
induction in mice with both heterozygous and wild type p53
alleles [38]. This protective effect was described also by Allay
et al., who reported that the incidence of lymphomas was much
lower in MGMT transgenic mice compared with controls [39].
Those studies thus suggest that MGMT, other than being
involved in the response to therapy, is also involved in DNA
repair. Therefore, its inactivation may produce devastating
effects on DNA integrity.
In summary, we have provided evidence of the existence of
an adjunct mechanism of MGMT regulation, besides promoter
methylation, involving miR targeting its 3’ UTR. We have also
shown that overexpression of miR-221/222 produces an
increase in sensitivity to TMZ via a reduction in the level of
MGMT. On the other hand, these miRs increase DNA damage,
conferring oncogenic features to glioma cells. This may link
miR-221/222 to poor GBM prognosis.
Supporting Information
Figure S1.  Methylation-specific PCR analyses for MGMT
methylation in glioblastoma human tumors. 33 glioblastoma
samples were used for analysis. The SW48 cell line and in vitro
methylated DNA (IVD) are shown as a positive control for
methylation, normal lymphocytes (NL) as a negative control for
methylation, and water (H2O) as a negative PCR control. U
and M indicate the presence of unmethylated or methylated
MGMT, respectively. Red colour is for methylated samples,
green for unmethylated and orange for undetermined samples.
(TIF)
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